

GCC Pharmaceutical Market Opportunity Insight 2025

https://marketpublishers.com/r/G59FEC836F10EN.html

Date: January 2020

Pages: 300

Price: US\$ 3,600.00 (Single User License)

ID: G59FEC836F10EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'GCC Pharmaceutical Market Opportunity Insight 2025' Report Highlights:

GCC Pharmaceutical Market Opportunity: > US\$ 20 Billion

Patented & OTC Pharmaceutical Market Size: 75% of Total Market

Share of Imported Drugs In GCC Pharmaceutical Market: > 80%

Saudi Arabia Dominates GCC Pharmaceutical Market: 50% Market Share

GCC Pharmaceutical Clinical Trials Insight: > 700 Drugs

The research report 'GCC Pharmaceutical Market Opportunity Insight 2025' provides an in-depth analysis about the current market dynamics that includes drivers, trends and opportunities which are subjected to have an influence on the market of the pharmaceutical products in the GCC region. Various important factors that are supported by the governments of the GCC countries for various agents commercialized in the region are also provided in a segmented way in the research report. The impact of the regulatory scenario that is prevailing upon the major key players of the region is also discussed in the report.

The research conducted on the respective subject highlights the distribution of the market based on the profiles of the companies and their respective efforts in increasing the production and value of the product exponentially. The anticipation of the pharmaceutical market in the GCC region is believed to be the result of the factors that



are hindering the people of GCC region such as rapid change in the dynamics of the population, geriatric population and most importantly increasing prevalence of lifestyle associated diseases such as diabetes, obesity, cardiovascular diseases.

'GCC Market Offers Unexplored & Exponential Growth Opportunities For Global Pharmaceutical Companies As Imports Accounts For More Than 80% Regional Pharmaceutical Products Sales.'

With the increasing disorders associated with lifestyle of the gulf population, the government policies along with regulatory framework became more poised towards the promoting the growth of the pharmaceutical market in the region. Factors like these are most prominent in developing a huge difference and marking an exponential growth rate in the market size of GCC pharmaceutical market in the coming years. Over the years, the branded drugs market has been dominating the market of GCC pharmaceuticals and most pre-dominantly among all the countries included in GCC, Saudi Arabia compiled of maximum share of the market.

Saudi Arabia, among the other gulf countries is a region with major dominant traits. Economic viability, changing legislative and framework are the main driving forces for the establishment of such high-valued pharmaceutical market in the gulf. Slowly and steadily, new frontiers of the pharmaceutical market are making their way to the gulf and imposing their need for the development of generic drug over the market of branded drugs. The alternative form of the drugs available in the market will end up in the upregulation of the overall market trends by many folds.

"The Growing Demand Of The Generic And Branded Pharmaceuticals That Is Driven By The Various Government Policies And Cost Effective Facilities, Is Considered As A Significant Opportunity For The Drug Manufacturers In The GCC."

The sales record achieved from the gulf countries establishes Saudi Arabia as an emerging ground for the pharmaceutical market, with UAE and others as a prominent region for expanding the market. The Imported drug market established in the region constitutes a major portion of the GCC pharmaceutical market. More than 80% of the drug utilized in the gulf countries is imported from the major players established in the Western countries. The percent mentioned indicates a huge demand of the drugs either imported or manufactured in the local region. Both aspects of the pharmaceutical market suggest a high demand of the pharmaceutical drugs in the market and eventually a prevailing commercial success.



Contents

1. INTRODUCTION TO GULF COOPERATION COUNCIL (GCC) PHARMACEUTICAL MARKET

- 1.1 Overview
- 1.2 GCC Pharmaceutical Market Analysis

2. GCC PHARMACEUTICAL MARKET BY INDICATION - PREVALENCE & STATISTICS

- 2.1 Cancer
 - 2.1.1 Overview
 - 2.1.2 Prevalence by Cancer Type & Gender
 - 2.1.3 Cancer Prevalence & Statistics by GCC Countries
- 2.2 Diabetes
- 2.3 HIV/AIDS
- 2.4 Cardiovascular Diseases
 - 2.4.1 Coronary Heart Disease
 - 2.4.2 Hypertension
 - 2.4.3 Stroke
- 2.5 Obesity
- 2.6 Respiratory Disorders
 - 2.6.1 Asthma
 - 2.6.2 Tuberculosis
 - 2.6.3 Influenza & Pneumonia
 - 2.6.4 Other Respiratory Diseases COPD & Cystic Fibrosis
- 2.7 Alzheimer's Disease/Dementia

3. GCC - REGULATORY ASPECTS OF PHARMACEUTICALS

- 3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
- 3.2 Regulatory Review Process
- 3.3 Centralized Registration
- 3.4 Decentralized Drug Registration Regulation
 - 3.4.1 Saudi Arabia
 - 3.4.2 Kuwait
 - 3.4.3 UAE
 - 3.4.4 Bahrain



- 3.4.5 Qatar
- 3.4.6 Oman
- 3.5 Gulf Joint Procurement Program

4. GCC - PHARMACEUTICAL PRICING & REIMBURSEMENT POLICIES

- 4.1 Pricing Policies
 - 4.1.1 In-Patent Pharmaceuticals
 - 4.1.2 Off-Patent & Generic Pharmaceuticals
 - 4.1.3 Locally & Multinational Manufactured Pharmaceuticals
- 4.2 Procurement & Reimbursement Policies
 - 4.2.1 In-Patent Pharmaceuticals
 - 4.2.2 Off-Patent, Generics & Biosimilars

5. GCC PHARMACEUTICAL MARKET BY PRODUCT

- 5.1Generics Pharmaceuticals
- 5.2 Patented & OTC Pharmaceuticals
- 5.3 Biosimilars

6. SAUDI ARABIA PHARMACEUTICAL MARKET ANALYSIS

- 6.1 Overview
- 6.2 Saudi Arabia Pharmaceutical Market by Products
- 6.3 Saudi Arabia Pharmaceutical Market by Companies
- 6.4 Saudi Arabia Pharmaceutical Market by Type

7. UAE PHARMACEUTICAL MARKET ANALYSIS

- 7.1 Overview
- 7.2 UAE Pharmaceuticals Market by Product
- 7.3 UAE Pharmaceutical Market by Companies
- 7.4 UAE Pharmaceutical Market by Type

8. KUWAIT PHARMACEUTICAL MARKET ANALYSIS

- 8.1 Overview
- 8.2 Kuwait Pharmaceutical Market by Therapeutic Indication & Products
- 8.3 Kuwait Pharmaceutical Market by Companies



8.4 Kuwait Pharmaceutical Market by Type

9. BAHRAIN PHARMACEUTICAL MARKET ANALYSIS

- 9.1 Overview
- 9.2 Bahrain Pharmaceutical Market by Products
- 9.3 Bahrain Pharmaceutical market by Companies
- 9.4 Bahrain Pharmaceutical Market by Product Type

10. QATAR PHARMACEUTICAL MARKET ANALYSIS

- 10.1 Overview
- 10.2 Qatar Pharmaceutical Market by Type

11. OMAN PHARMACEUTICAL MARKET ANALYSIS

- 11.1 Overview
- 11.2 Oman Pharmaceutical Market by Product Type

12. GCC PHARMACEUTICAL MARKET - INTERNATIONAL TRADE

- 12.1 Import Market
- 12.2 Pharmaceutical Export Market

13. GCC PHARMACEUTICAL MARKET - CLINICAL INSIGHT

- 13.1 Overview
- 13.2 Clinical Trials by Indication
 - 13.2.1 Cancer
 - 13.2.2 Diabetes
 - 13.2.3 CVS Disorders
 - 13.2.4 Respiratory Disorders
- 13.3 Clinical Insight by GCC Countries
 - 13.3.1 Saudi Arabia
 - 13.3.2 United Arab Emirates
 - 13.3.3 Kuwait
 - 13.3.4 Bahrain
 - 13.3.5 Qatar
 - 13.3.6 Oman



14. GCC PHARMACEUTICAL MARKET DRIVERS

15. CHALLENGES FOR GCC PHARMACEUTICAL MARKET

16. GCC PHARMACEUTICAL MARKET FUTURE OUTLOOK - TRENDS & OPPORTUNITIES

17. COMPETITIVE LANDSCAPE

17.1	Local	Pharmaceutical	Companies
------	-------	----------------	-----------

- 17.1.1 Julphur Pharmaceuticals
- 17.1.2 SPIMACO Addwaeih
- 17.1.3 Qatar Life Pharma
- 17.1.4 Al Mojil Drug Company
- 17.1.5 Kuwait Saudi Pharmaceutical Company
- 17.1.6 YIACO Medical Company
- 17.1.7 Qatar Pharma
- 17.1.8 Saja Pharmaceuticals
- 17.1.9 Oman Pharmaceuticals
- 17.1.10 Taiba Pharmaceuticals
- 17.1.11 Gulf Biotech
- 17.1.12 Bahrain Pharma
- 17.1.13 Neopharma
- 17.1.14 Planet Pharmacies
- 17.1.15 Aljazeera Pharmaceutical Industries
- 17.1.16 Dallah Pharma
- 17.1.17 Tabuk Pharmaceuticals
- 17.1.18 CAD Middle-East Pharmaceutical Company
- 17.1.19 ACDIMA
- 17.1.20 AL-Mufid Pharmaceuticals
- 17.2 Multinational Companies
 - 17.2.1 Novartis
 - 17.2.2 Amgen
 - 17.2.3 Eli Lilly
 - 17.2.4 Merck
 - 17.2.5 Pfizer
 - 17.2.6 GlaxoSmithKline plc
 - 17.2.7 Roche



17.2.8 Takeda Pharmaceuticals

17.2.9 Teva Pharmaceuticals

17.2.10 AstraZeneca plc

17.2.11 Genentech

17.2.12 Sanofi



List Of Figures

LIST OF FIGURES

Figure 1-1: Pharmaceutical Market Size - Global vs. GCC (US\$ Billion), 2018

Figure 1-2: GCC vs. Rest of World - Pharmaceutical Market Size (%), 2018

Figure 1-3: GCC - Population Statistics (Million), 2019

Figure 1-4: GCC - Population by Countries (%), 2019

Figure 1-5: GCC - Healthcare Expenditure by Countries (US\$ Billion), 2018

Figure 1-6: GCC - Healthcare Expenditure by Countries (%), 2018

Figure 1-7: GCC - Pharmaceutical Market Size (US\$ Billion), 2016 & 2018

Figure 1-8: GCC Pharmaceutical Market Size (US\$ Billion), 2018 - 2025

Figure 1-9: MEA vs. GCC - Pharmaceutical Market Size (US\$ Billion), 2018

Figure 1-10: GCC vs. Rest of MEA - Pharmaceutical Market Size (%), 2018

Figure 1-11: GCC - Pharmaceutical Market Size by Countries (US\$ Billion), 2018

Figure 1-12: Pharmaceutical Market Size of Various GCC Countries (%), 2018

Figure 2-1: GCC - Number of Newly Diagnosed Cancer Cases & Deaths, 2018

Figure 2-2: GCC - Number of New Cancer Cases by Countries, 2018

Figure 2-3: GCC - New Cancer Cases by Countries (%), 2018

Figure 2-4: GCC - Number of Cancer Related Deaths by Countries, 2018

Figure 2-5: GCC - New Cancer Cases by Countries (%), 2018

Figure 2-6: GCC - Number of Newly Diagnosed Cancer Cases, 2018 & 2030

Figure 2-7: GCC - Age Standardized Cancer Incidence Rate by Countries (per 100,000

People), 2018

Figure 2-8: GCC - Age Standardized Cancer Mortality Rate by Countries (per 100,000

People), 2018

Figure 2-9: GCC Pharmaceutical Market Size - Total vs. Cancer Drugs (US\$ Billion),

2018

Figure 2-10: GCC - Cancer Drug Market Size by Countries (%), 2018

Figure 2-11: GCC - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-12: GCC - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-13: GCC - Number of Cancer Cases & Deaths by Gender, 2018

Figure 2-14: GCC - Cancer Cases by Gender (%), 2018

Figure 2-15: GCC - Cancer Deaths by Gender (%), 2018

Figure 2-16: GCC - Age Standardized Cancer Incidence & Mortality Rate (per 100,000

People), 2018

Figure 2-17: Saudi Arabia - Number of Cancer Cases & Deaths, 2018

Figure 2-18: Saudi Arabia - Number of Cancer Cases & Deaths by Gender, 2018

Figure 2-19: Saudi Arabia - New Diagnosed Cancer Cases by Gender (%), 2018



- Figure 2-20: Saudi Arabia Cancer Related Deaths by Gender (%), 2018
- Figure 2-21: Saudi Arabia New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-22: UAE Number of Cancer Cases & Deaths, 2018
- Figure 2-23: UAE Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-24: UAE New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-25: UAE Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-26: Kuwait Number of Cancer Cases & Deaths, 2018
- Figure 2-27: Kuwait Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-28: Kuwait New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-29: Kuwait Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-30: Bahrain Number of Cancer Cases & Deaths, 2018
- Figure 2-31: Bahrain Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-32: Bahrain New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-33: Bahrain Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-34: Qatar Number of Cancer Cases & Deaths, 2018
- Figure 2-35: Qatar Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-36: Qatar New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-37: Qatar Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-38: Oman Number of Cancer Cases & Deaths, 2018
- Figure 2-39: Oman Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-40: Oman New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-41: Oman Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-42: GCC Total Adult Population & Diabetic Population (Million), 2017
- Figure 2-43: GCC Total Adult Population & Diabetic Population (%), 2017
- Figure 2-44: GCC Diabetic Population by Countries (Million), 2017
- Figure 2-45: GCC Diabetic Population by Countries (%), 2017
- Figure 2-46: GCC Diabetes Related Deaths by Countries, 2017
- Figure 2-47: GCC Diabetes Related Deaths by Countries (%), 2017
- Figure 2-48: GCC Diabetes Prevalence Rate by Countries (%), 2017
- Figure 2-49: GCC Age Standardized Diabetes Death Rate by Countries (Per 100,000
- People), 2017
- Figure 2-50: GCC Diabetic Population (Billion), 2017, 2018 & 2045
- Figure 2-51: Saudi Arabia Total HIV Cases & Newly Diagnosed HIV Cases, 2017
- Figure 2-52: Saudi Arabia New Diagnosed HIV Cases, 2013 2017
- Figure 2-53: Saudi Arabia New Diagnosed HIV Cases by Gender, 2017
- Figure 2-54: Saudi Arabia New Diagnosed HIV Cases by Gender (%), 2017
- Figure 2-55: Saudi Arabia Total HIV Cases by Gender, 2017
- Figure 2-56: Saudi Arabia Total HIV Cases by Gender, 2017
- Figure 2-57: Saudi Arabia Cumulative HIV Related Deaths by Gender, 2017



Figure 2-58: Saudi Arabia - Cumulative Number of HIV Patients on Anti-retroviral

Therapy, 2017

Figure 2-59: UAE - Cumulative Number of HIV Patients, 2012, 2014 & 2016

Figure 2-60: UAE - Number of New HIV Cases & Deaths, 2016

Figure 2-61: UAE - Cumulative Number of HIV Patients on Anti-retroviral Therapy,

2012, 2014 & 2018

Figure 2-62: UAE - Cumulative Number of HIV Patients, 2014 - 2018

Figure 2-63: Bahrain - HIV Associated New Cases & Deaths, 2016

Figure 2-64: Bahrain - Patients Receiving Antiretroviral Therapy (%), 2012, 2014 & 2016

Figure 2-65: Qatar - Cumulative Number of HIV Cases & Patients on Antiretroviral

Therapy, 1984 - 2014

Figure 2-66: Qatar - HIV Patients on Anti-Retroviral Therapy, 1984 - 2014

Figure 2-67: Oman - Cumulative HIV Cases, 2014, 2016 & 2018

Figure 2-68: Oman - Cumulative HIV Cases by Gender, 2018

Figure 2-69: Oman - Cumulative HIV Cases by Gender (%), 2018

Figure 2-70: Oman - Cumulative HIV Cases by Age, 2018

Figure 2-71: GCC - Age Standardized Coronary Heart Disease Death Rate by

Countries, 2017

Figure 2-72: GCC - CHD Related Deaths by Countries, 2017

Figure 2-73: GCC - CHD Related Deaths by Countries (%), 2017

Figure 2-74: GCC - Age Standardized Hypertension Death Rate by Countries, 2017

Figure 2-75: GCC - Hypertension Related Deaths by Countries, 2017

Figure 2-76: GCC - Hypertension Related Deaths by Countries (%), 2017

Figure 2-77: GCC - Age Standardized Stroke Death Rate by Countries, 2017

Figure 2-78: GCC - Stroke Related Deaths by Countries, 2017

Figure 2-79: GCC - Stroke Related Deaths by Countries (%), 2017

Figure 2-80: GCC - Obese Population by Countries (%), 2019

Figure 2-81: GCC - Body Mass Index by Countries, 2019

Figure 2-82: Saudi Arabia - Obesity Prevalence Rate (%), 2017 & 2022

Figure 2-83: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2017 & 2022

Figure 2-84: UAE - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-85: UAE - Obese Adult Population (%), 2019

Figure 2-86: Kuwait - Prevalence Rate of Obesity & Overweight (%), 2016

Figure 2-87: Kuwait - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-88: Bahrain - Prevalence Rate of Obesity & Overweight (%), 2016

Figure 2-89: Bahrain - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-90: Qatar - Prevalence Rate of Obesity & Overweight (%), 2016

Figure 2-91: Qatar - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-92: Oman - Obesity Prevalence Rate by Gender (%), 2016



Figure 2-93: GCC - Asthma Related Deaths by Countries, 2017

Figure 2-94: GCC - Asthma Related Deaths by Countries (%), 2017

Figure 2-95: GCC - Age Standardized Asthma Death Rate by Countries (per 100,000

People), 2017

Figure 2-96: GCC - Tuberculosis Related Deaths by Countries, 2017

Figure 2-97: GCC - Age Standardized Incidence Rate of Tuberculosis by Countries (Per

100,000 People), 2017

Figure 2-98: GCC - Asthma Related Deaths by Countries (%), 2017

Figure 2-99: GCC - Age Standardized Tuberculosis Death Rate by Countries (per

100,000 People), 2017

Figure 2-100: GCC - Influenza & Pneumonia Related Deaths by Countries, 2017

Figure 2-101: GCC - Influenza & Pneumonia Related Deaths by Countries (%), 2017

Figure 2-102: GCC - Age Standardized Influenza & Pneumonia Death Rate by

Countries (per 100,000 People), 2017

Figure 2-103: GCC - COPD Prevalence Rate by Countries (%), 2018

Figure 2-104: GCC - COPD & Cystic Fibrosis Related Deaths by Countries, 2017

Figure 2-105: GCC - COPD & Cystic Fibrosis Related Deaths by Countries (%), 2017

Figure 2-106: GCC - Age Standardized COPD & Cystic Fibrosis Death Rate by

Countries (per 100,000 People), 2017

Figure 2-107: GCC - Alzheimer/Dementia Related Deaths by Countries, 2017

Figure 2-108: GCC - Alzheimer/Dementia Related Deaths by Countries (%), 2017

Figure 2-109: GCC - Age Standardized Alzheimer/Dementia Death Rate by Countries

(per 100,000 People), 2017

Figure 3-1: GCC - Types of Drug Registration Process

Figure 3-2: Process Map for GCC Centralized Registration

Figure 3-3: GCC - Innovative/Biological and Generic Drug Registration Fees for

Evaluation Procedures (SAR/US\$), 2019

Figure 3-4: GCC - Innovative/Biological and Generic Drug Registration Renewal Fees

(SAR/US\$), 2019

Figure 3-5: GCC - Registration Fees for Addition of New Pharmaceutical Form, New

Strength & New Pack Size for Innovative/Biological Products (SAR/US\$), 2019

Figure 3-6: GCC - Registration Fees for Addition of New Pharmaceutical Form, New

Strength & New Pack Size for Generic Products (SAR/US\$), 2019

Figure 3-7: GCC - Registration Fees for Addition of New Pharmaceutical Form, New

Strength & New Pack Size for Intravenous Generic Products (SAR/US\$), 2019

Figure 3-8: Saudi Arabia - Regulatory Process for Pharmaceuticals

Figure 3-9: Kuwait - Regulatory Process for Pharmaceuticals

Figure 3-10: UAE - Regulatory Process for Pharmaceuticals

Figure 3-11: Bahrain - Regulatory Process for Pharmaceuticals



- Figure 3-12: Qatar Regulatory Process for Pharmaceuticals
- Figure 3-13: Oman Regulatory Process for Pharmaceuticals
- Figure 5-1: GCC Pharmaceutical Market Size Generic vs. Others (US\$ Billion), 2018
- Figure 5-2: GCC Pharmaceutical Market Size Generic vs. Others (%), 2018
- Figure 5-3: GCC Generic Drug Market Size (US\$ Billion), 2018 2025
- Figure 5-4: GCC Patented & OTC Pharmaceutical Market Size (US\$ Billion), 2018
- Figure 5-5: GCC Share of Patented Products in Pharmaceutical Market by Countries (%), 2016
- Figure 5-6: GCC Share of OTC Products in Pharmaceutical Market by Countries (%), 2016
- Figure 5-7: GCC Biosimilars Market Size (US\$ Million), 2019 & 2025
- Figure 5-8: GCC Strategies Considered by New Biosimilars Manufacturers
- Figure 5-9: Key Stakeholders for Launch of Biosimilars
- Figure 6-1: Pharmaceutical Market Size Saudi Arabia vs. Rest of GCC (%), 2018
- Figure 6-2: Pharmaceutical Market Size Saudi Arabia vs. Rest of MEA (%), 2018
- Figure 6-3: Saudi Arabia Pharmaceutical Market Size (US\$ Billion), 2018 2025
- Figure 6-4: Saudi Arabia Pharmaceutical Market Share by Channel of Distribution (%), 2018
- Figure 6-5: Saudi Arabia Pharmaceutical Market Size by indication (%), 2018
- Figure 6-6: Saudi Arabia Number of New Product Launched by Indication, 2018
- Figure 6-7: Saudi Arabia Sales Data of Leading Pharmaceutical Products (US\$ Million), 2018
- Figure 6-8: Saudi Arabia Revenue of Leading Pharmaceutical Companies (US\$ Million), 2018
- Figure 6-9: Saudi Arabia Generic & Branded Pharmaceutical Market Size (%), 2018
- Figure 6-10: Saudi Arabia OTC & Prescribed Pharmaceuticals Market Size (US\$ Billion), 2018
- Figure 6-11: Saudi Arabia OTC & Prescribed Pharmaceutical Market Size (%), 2018
- Figure 7-1: Pharmaceutical Market Size UAE vs. Rest of GCC (%), 2018
- Figure 7-2: Pharmaceutical Market Size UAE vs. Rest of MEA (%), 2018
- Figure 7-3: UAE Pharmaceutical Market Size by Channel of Distribution (%), 2018
- Figure 7-4: UAE Pharmaceutical Market Size (US\$ Billion), 2018 2025
- Figure 7-5: UAE Pharmaceutical Export Market by Region (%), 2017
- Figure 7-6: UAE Pharmaceutical Export Market by Countries (%), 2017
- Figure 7-7: UAE Pharmaceutical Export Market by Products (%), 2018
- Figure 7-8: UAE Pharmaceutical Market Size by Therapeutic Indication (US\$ Million), 2018
- Figure 7-9: UAE Number of New Launched Pharmaceutical Product by Indication, 2018



- Figure 7-10: UAE Growth Rate of Leading Pharmaceutical Companies (%), 2018
- Figure 7-11: UAE Pharmaceutical Market Share by Type of Products (%), 2017
- Figure 7-12: UAE Pharmaceutical Market Share by Type of Products (%), 2018
- Figure 7-13: UAE Generic Drug Market Size (US\$ Million), 2017 2025
- Figure 8-1: Pharmaceutical Market Size Kuwait vs. Rest of GCC (%), 2018
- Figure 8-2: Pharmaceutical Market Size Kuwait vs. Rest of MEA (%), 2018
- Figure 8-3: Kuwait Pharmaceutical Market Size (US\$ Billion), 2018-2025
- Figure 8-4: Kuwait Pharmaceutical Market Size by Therapeutic Indication (%), 2018
- Figure 8-5: Kuwait Sales Data of Leading Pharmaceutical Products (US\$ Million), 2018
- Figure 8-6: Kuwait Pharmaceutical Market Size MNC vs. Regional Companies (%), 2016
- Figure 8-7: Kuwait Julphar Pharmaceutical Share in Regional Pharmaceutical sales (%), 2016
- Figure 8-8: Kuwait Pharmaceutical Market Size by Leading Companies (US\$ Million), 2018
- Figure 8-9: Kuwait Generic Pharmaceutical Market Share (%), 2018 & 2025
- Figure 8-10: Kuwait Pharmaceutical Market by Type of Product (%), 2018
- Figure 8-11: Kuwait Generic Drug Market Share in Total market Size (%), 2018
- Figure 8-12: Kuwait OTC Pharmaceutical Market Share (%), 2018 & 2025
- Figure 9-1: Bahrain Pharmaceutical Market Size Bahrain vs. Rest of GCC (%), 2018
- Figure 9-2: Bahrain Pharmaceutical Market Size (US\$ Million), 2018 2025
- Figure 9-3: Bahrain Pharmaceutical Market Size Import vs. Total Market (US\$ Million), 2018
- Figure 9-4: Bahrain Pharmaceutical market Share Import vs. Other Market (%), 2018
- Figure 9-5: Bahrain Pharmaceutical market Share by Therapeutic Agents (%), 2018
- Figure 9-6: Bahrain Market Size by Leading Pharmaceutical Companies (US\$ Million), 2018
- Figure 9-7: Bahrain Share of Generics in Total Pharmaceutical Market (%) 2018 & 2025
- Figure 9-8: Bahrain Share of OTC in Total Pharmaceutical Market (%) 2018 & 2025
- Figure 9-9: Bahrain Patented, Generics & OTC Pharmaceuticals Market Share (%), 2018
- Figure 9-10: Bahrain Patented, Generics & OTC Pharmaceuticals Market Share (%), 2025
- Figure 9-11: Bahrain Generic Pharmaceutical Market Size (US\$ Million), 2018 & 2025
- Figure 9-12: Bahrain OTC Pharmaceutical Market Size (US\$ Million), 2018 & 2025
- Figure 10-1: Qatar Pharmaceutical Market Size (US\$ Million), 2015 2018
- Figure 10-2: Qatar Pharmaceutical Market Size Qatar vs. Rest of GCC (%), 2018



- Figure 10-3: Qatar Pharmaceutical Market Size Qatar vs. Rest of MEA (%), 2018
- Figure 10-4: Qatar Pharmaceutical Market Size (US\$ Million), 2018 2025
- Figure 10-5: Qatar Pharmaceutical Market Size by Product Type (US\$ Million), 2018
- Figure 10-6: Qatar Pharmaceutical Market Size by Product Type (%), 2018
- Figure 10-7: Qatar Pharmaceutical Market Size by Type of Product (US\$ Million), 2025
- Figure 11-1: Oman Pharmaceutical Market Size (US\$ Million), 2012, 2016 & 2018
- Figure 11-2: Pharmaceutical Market Size Oman vs. Rest of GCC (%), 2018
- Figure 11-3: Pharmaceutical Market Size Oman vs. Rest of MEA (%), 2018
- Figure 11-4: Oman Pharmaceutical Market Size (US\$ million), 2019 2025
- Figure 11-5: Oman Import, Export & Other Pharmaceutical Market Size (US\$ Million), 2018
- Figure 11-6: Oman Import, Export & Other Pharmaceutical Market Size (%), 2018
- Figure 11-7: Oman Share of Generics in Total Pharmaceutical Market (%) 2016, 2018 & 2025
- Figure 11-8: Oman Share of OTC in Total Pharmaceutical Market (%) 2016, 2018 & 2025
- Figure 11-9: Oman Patented, Generics & OTC Pharmaceuticals Market Share (%), 2018
- Figure 11-10: Oman Patented, Generics & OTC Pharmaceuticals Market Share (%), 2025
- Figure 11-11: Oman Generic Pharmaceutical Market Size (US\$ Million), 2018 & 2025
- Figure 11-12: Oman OTC Pharmaceutical Market Size (US\$ Million), 2018 & 2025
- Figure 12-1: GCC Pharmaceutical Import Market Size by Countries (US\$ Billion), 2018
- Figure 12-2: GCC Pharmaceutical Import Market Size by Countries (%), 2018
- Figure 12-3: GCC Import Pharmaceutical Market Size (US\$ Billion), 2016, 2017 & 2018
- Figure 12-4: Saudi Arabia Pharmaceutical Import Size (US\$ Billion), 2016 2018
- Figure 12-5: UAE Pharmaceutical Import Size (US\$ Billion), 2016 2018
- Figure 12-6: Kuwait Pharmaceutical Import Size (US\$ Billion), 2016 2018
- Figure 12-7: Bahrain Pharmaceutical Import Size (US\$ Million), 2016 2018
- Figure 12-8: Qatar Pharmaceutical Import Size (US\$ Million), 2016 2018
- Figure 12-9: Oman Pharmaceutical Import Size (US\$ Million), 2016 2018
- Figure 12-10: GCC Pharmaceutical Export Market Size by Countries (US\$ Million), 2018
- Figure 12-11: GCC Pharmaceutical Export Market Size by Countries (%), 2018
- Figure 12-12: GCC Export Pharmaceutical Market Size (US\$ Billion), 2016, 2017 & 2018
- Figure 12-13: Saudi Arabia Pharmaceutical Export Size (US\$ Million), 2016 2018
- Figure 12-14: UAE Pharmaceutical Export Size (US\$ Million), 2016 2018



- Figure 12-15: Kuwait Pharmaceutical Export Size (US\$ Million), 2016 2018
- Figure 12-16: Bahrain Pharmaceutical Export Size (US\$ Million), 2016 2018
- Figure 12-17: Qatar Pharmaceutical Export Size (US\$ Million), 2016 2018
- Figure 12-18: Oman Pharmaceutical Export Size (US\$ Million), 2016 2018
- Figure 13-1: GCC Number of Clinical Trials by Countries, 2019
- Figure 13-2: GCC Clinical Trials by Countries (%), 2019
- Figure 13-3: GCC Number of Clinical Trials by Status, 2019
- Figure 13-4: GCC Clinical Trials by Status (%), 2019
- Figure 13-5: GCC Number of Clinical Trial by Phase, 2019
- Figure 13-6: GCC Number of Clinical Trial by Phase (%), 2019
- Figure 13-7: GCC Numbers of Clinical Trials by Indications, 2019
- Figure 13-8: GCC Clinical Trials by Indications (%), 2019
- Figure 13-9: GCC Number of Cancer Related Clinical Trials by Countries, 2019
- Figure 13-10: GCC Cancer Related Clinical Trials by Countries (%), 2019
- Figure 13-11: GCC Number of Cancer Related Clinical Trials by Phase of
- Development, 2019
- Figure 13-12: GCC Number of Diabetes Related Clinical Trials by Countries, 2019
- Figure 13-13: GCC Diabetes Related Clinical Trials by Countries (%), 2019
- Figure 13-14: GCC Number of Diabetes Related Clinical Trials by Development Phase, 2019
- Figure 13-15: GCC Number of CVS Disorder Related Clinical Trials by Countries, 2019
- Figure 13-16: GCC CVS Disorder Related Clinical Trials by Countries (%), 2019
- Figure 13-17: GCC Number of CVS Disorders Related Clinical Trials by Development Phase, 2019
- Figure 13-18: GCC Number of Respiratory Disorder (Except Lung Cancer) Related Clinical trials by Countries, 2019
- Figure 13-19: GCC Respiratory Disorder (Except Lung Cancer) Related Clinical Trials by Countries (%), 2019
- Figure 13-20: GCC Number of Respiratory Disorders Related Clinical Trials by Development Phase, 2019
- Figure 13-21: Saudi Arabia Number of Clinical Trials by Development Phase, 2019
- Figure 13-22: Saudi Arabia Number of Clinical Trials by Status, 2019
- Figure 13-23: Saudi Arabia Numbers of Clinical Trials by Indications, 2019
- Figure 13-24: Saudi Arabia Clinical Trials by Indications (%), 2019
- Figure 13-25: UAE Clinical Trials in States of UAE (%), 2019
- Figure 13-26: UAE Number of Clinical Trials by Development Phase, 2019
- Figure 13-27: UAE Number of Clinical Trials by Status, 2019
- Figure 13-28: UAE Numbers of Clinical Trials by Indications, 2019



Figure 13-29: UAE - Clinical Trials by Indications (%), 2019

Figure 13-30: Kuwait - Number of Clinical Trials by Development Phase, 2019

Figure 13-31: Kuwait - Number of Clinical Trials by Status, 2019

Figure 13-32: Kuwait - Numbers of Clinical Trials by Indications, 2019

Figure 13-33: Kuwait - Clinical Trials by Indications (%), 2019

Figure 13-34: Bahrain - Number of Clinical Trials by Development Phase, 2019

Figure 13-35: Bahrain - Number of Clinical Trials by Status, 2019

Figure 13-36: Qatar - Number of Clinical Trials by Development Phase, 2019

Figure 13-37: Qatar - Number of Clinical Trials by Status, 2019

Figure 13-38: Qatar - Numbers of Clinical Trials by Indications, 2019

Figure 13-39: Kuwait - Clinical Trials by Indications (%), 2019

Figure 13-40: Oman - Number of Clinical Trials by Development Phase, 2019

Figure 13-41: Oman - Number of Clinical Trials by Status, 2019

Figure 14 1: Driving Factors for GCC Pharmaceutical Market

Figure 15-1: Challenges for GCC Pharmaceutical Market

Figure 16-1: GCC - Population Forecast by Countries (Million), 2025

Figure 16-2: GCC - Pharmaceutical Market Forecast by Countries (US\$ Billion), 2025

Figure 16-3: GCC - Pharmaceutical Market Share Forecast by Countries (%), 2025

Figure 16-4: GCC - Cancer Drug Market Forecast (US\$ Billion), 2018 & 2025

Figure 16-5: GCC - Generic Pharmaceutical Market Forecast (%), 2025



I would like to order

Product name: GCC Pharmaceutical Market Opportunity Insight 2025
Product link: https://marketpublishers.com/r/G59FEC836F10EN.html

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G59FEC836F10EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970